|
1
|
Michalski MN and McCauley LK: Macrophages
and skeletal health. Pharmacol Ther. 174:43–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kular J, Tickner J, Chim SM and Xu J: An
overview of the regulation of bone remodelling at the cellular
level. Clin Biochem. 45:863–873. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sobh MM, Abdalbary M, Elnagar S, Nagy E,
Elshabrawy N, Abdelsalam M, Asadipooya K and El-Husseini A:
Secondary osteoporosis and metabolic bone diseases. J Clin Med.
11:23822022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han Y, You X, Xing W, Zhang Z and Zou W:
Paracrine and endocrine actions of bone-the functions of secretory
proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res.
6:162018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bae SJ, Shin MW, Son T, Lee HS, Chae JS,
Jeon S, Oh GT and Kim KW: Ninjurin1 positively regulates osteoclast
development by enhancing the survival of prefusion osteoclasts. Exp
Mol Med. 51:1–16. 2019.
|
|
7
|
Chen K, Qiu P, Yuan Y, Zheng L, He J, Wang
C, Guo Q, Kenny J, Liu Q, Zhao J, et al: Pseurotin A inhibits
osteoclastogenesis and prevents ovariectomized-induced bone loss by
suppressing reactive oxygen species. Theranostics. 9:1634–1650.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Li J, Xie X, Gu F, Sui Z, Zhang K
and Yu T: Macrophage-osteoclast associations: Origin, polarization,
and subgroups. Front Immunol. 12:7780782021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tobeiha M, Moghadasian MH, Amin N and
Jafarnejad S: RANKL/RANK/OPG pathway: A mechanism involved in
exercise-induced bone remodeling. Biomed Res Int. 2020:69103122020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asagiri M and Takayanagi H: The molecular
understanding of osteoclast differentiation. Bone. 40:251–264.
2007. View Article : Google Scholar
|
|
11
|
Takayanagi H: The role of NFAT in
osteoclast formation. Ann N Y Acad Sci. 1116:227–237. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grigoriadis AE, Wang ZQ, Cecchini MG,
Hofstetter W, Felix R, Fleisch HA and Wagner EF: c-Fos: A key
regulator of osteoclast-macrophage lineage determination and bone
remodeling. Science. 266:443–448. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bellavia D, Dimarco E, Costa V, Carina V,
De Luca A, Raimondi L, Fini M, Gentile C, Caradonna F and Giavaresi
G: Flavonoids in bone erosive diseases: Perspectives in
osteoporosis treatment. Trends Endocrinol Metab. 32:76–94. 2021.
View Article : Google Scholar
|
|
14
|
Mesaik MA, Murad S, Khan KM, Tareen RB,
Ahmed A and Choudhary MI: Isolation and immunomodulatory properties
of a flavonoid, casticin from Vitex agnus-castus. Phytother Res.
23:1516–1520. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan EWC, Wong SK and Chan HT: Casticin
from Vitex species: A short review on its anticancer and
anti-inflammatory properties. J Integr Med. 16:147–152. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ramchandani S, Naz I, Lee JH, Khan MR and
Ahn KS: An overview of the potential antineoplastic effects of
casticin. Molecules. 25:12872020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun C, Yan H, Jiang K and Huang L:
Protective effect of casticin on experimental skin wound healing of
rats. J Surg Res. 274:145–152. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JH, Lee S, Nguyen QN, Phung HM, Shin
MS, Kim JY, Choi H, Shim SH and Kang KS: Identification of the
active ingredient and beneficial effects of Vitex rotundifolia
fruits on menopausal symptoms in ovariectomized rats. Biomolecules.
11:10332021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Qiu C, Xu P, Lu Y and Chen R:
Casticin improves respiratory dysfunction and attenuates oxidative
stress and inflammation via inhibition of NF-ĸB in a chronic
obstructive pulmonary disease model of chronic cigarette
Smoke-exposed rats. Drug Des Devel Ther. 14:5019–5027. 2020.
View Article : Google Scholar :
|
|
20
|
Xu J, Wu HF, Ang ES, Yip K, Woloszyn M,
Zheng MH and Tan RX: NF-kappaB modulators in osteolytic bone
diseases. Cytokine Growth Factor Rev. 20:7–17. 2009. View Article : Google Scholar
|
|
21
|
Qin A, Cheng TS, Lin Z, Pavlos NJ, Jiang
Q, Xu J, Dai KR and Zheng MH: Versatile roles of V-ATPases
accessory subunit Ac45 in osteoclast formation and function. PLoS
One. 6:e271552011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Xiao L, Zhong M, Huang Y, Zhu J, Tang W,
Li D, Shi J, Lu A, Yang H, Geng D, et al: Puerarin alleviates
osteoporosis in the ovariectomy-induced mice by suppressing
osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB
signaling pathways. Aging (Albany NY). 12:21706–21729. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sapra L, Shokeen N, Porwal K, Saini C,
Bhardwaj A, Mathew M, Mishra PK, Chattopadhyay N, Dar HY, Verma B
and Srivastava RK: Bifidobacterium longum ameliorates
ovariectomy-induced bone loss via enhancing anti-osteoclastogenic
and immunomodulatory potential of regulatory B cells (Bregs). Front
Immunol. 13:8757882022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, Mei W, Huang Z, Zhang L, Zhang L, Xu
B, Shi X, Xiao Y, Ma Z, Liao T, et al: Casticin suppresses
monoiodoacetic acid-induced knee osteoarthritis through inhibiting
HIF-1α/NLRP3 inflammasome signaling. Int Immunopharmacol.
86:1067452020. View Article : Google Scholar
|
|
26
|
Teitelbaum SL: Bone resorption by
osteoclasts. Science. 289:1504–1508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pereira M, Petretto E, Gordon S, Bassett
JHD, Williams GR and Behmoaras J: Common signalling pathways in
macrophage and osteoclast multinucleation. J Cell Sci.
131:jcs2162672018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adamik J, Pulugulla SH, Zhang P, Sun Q,
Lontos K, Macar DA, Auron PE and Galson DL: EZH2 supports
osteoclast differentiation and bone resorption via epigenetic and
cytoplasmic targets. J Bone Miner Res. 35:181–195. 2020. View Article : Google Scholar
|
|
29
|
Khosla S, Oursler MJ and Monroe DG:
Estrogen and the skeleton. Trends Endocrinol Metab. 23:576–581.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song S, Guo Y, Yang Y and Fu D: Advances
in pathogenesis and therapeutic strategies for osteoporosis.
Pharmacol Ther. 237:1081682022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim HS, Jung HY, Kim MO, Joa KL, Kim YJ,
Kwon SY and Kim CH: Successful conservative treatment: Multiple
atypical fractures in osteoporotic patients after bisphosphate
medication: A unique case report. Medicine (Baltimore).
94:e4462015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang X, Liang J, Wang Z, Su Y, Zhan Y, Wu
Z, Li J, Li X, Chen R, Zhao J, et al: Sesamolin protects mice from
ovariectomized bone loss by inhibiting osteoclastogenesis and
RANKL-mediated NF-κB and MAPK signaling pathways. Front Pharmacol.
12:6646972021. View Article : Google Scholar
|
|
33
|
Xian Y, Su Y, Liang J, Long F, Feng X,
Xiao Y, Lian H, Xu J, Zhao J, Liu Q and Song F: Oroxylin A reduces
osteoclast formation and bone resorption via suppressing
RANKL-induced ROS and NFATc1 activation. Biochem Pharmacol.
193:1147612021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding D, Yan J, Feng G, Zhou Y, Ma L and
Jin Q: Dihydroartemisinin attenuates osteoclast formation and bone
resorption via inhibiting the NF-κB, MAPK and NFATc1 signaling
pathways and alleviates osteoarthritis. Int J Mol Med. 49:42022.
View Article : Google Scholar
|
|
35
|
Kowalski M, Assa A, Patil K, Terrell C,
Holliday N and Pai SB: Casticin impacts key signaling pathways in
colorectal cancer cells leading to cell death with therapeutic
implications. Genes (Basel). 13:8152022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan L, Zhang Y, Zhou Q, Liu Y, Gong B, Lü
J, Zhu H, Zhu G, Xu Y and Huang G: Casticin inhibits breast cancer
cell migration and invasion by down-regulation of PI3K/Akt
signaling pathway. Biosci Rep. 38:BSR201807382018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang L, You X, Zhang L, Zhang C and Zou W:
Mechanical regulation of bone remodeling. Bone Res. 10:162022.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takayanagi H: RANKL as the master
regulator of osteoclast differentiation. J Bone Miner Metab.
39:13–18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun Y, Li J, Xie X, Gu F, Sui Z, Zhang K
and Yu T: Recent advances in osteoclast biological behavior. Front
Cell Dev Biol. 9:7886802021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Novack DV: Role of NF-κB in the skeleton.
Cell Res. 21:169–182. 2011. View Article : Google Scholar
|
|
41
|
Cao H, Zhu K, Qiu L, Li S, Niu H, Hao M,
Yang S, Zhao Z, Lai Y, Anderson JL, et al: Critical role of AKT
protein in myeloma-induced osteoclast formation and osteolysis. J
Biol Chem. 288:30399–30410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Soysa NS, Alles N, Aoki K and Ohya K:
Osteoclast formation and differentiation: an overview. J Med Dent
Sci. 59:65–74. 2012.PubMed/NCBI
|
|
43
|
Jo YJ, Lee HI, Kim N, Hwang D, Lee J, Lee
GR, Hong SE, Lee H, Kwon M, Kim NY, et al: Cinchonine inhibits
osteoclast differentiation by regulating TAK1 and AKT, and promotes
osteogenesis. J Cell Physiol. 236:1854–1865. 2021. View Article : Google Scholar
|
|
44
|
Sitara D and Aliprantis AO:
Transcriptional regulation of bone and joint remodeling by NFAT.
Immunol Rev. 233:286–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu W, Chen X, Wang Y, Fan B, Guo K, Yang
C, Yu S, Pang Y and Zhang S: Chitooligosaccharide inhibits
RANKL-induced osteoclastogenesis and ligation-induced periodontitis
by suppressing MAPK/c-fos/NFATC1 signaling. J Cell Physiol.
235:3022–3032. 2020. View Article : Google Scholar
|
|
46
|
Zhang Q, Hu S, He Y, Song Z, Shen Y, Zhao
Z and Zhang Q, Qin L and Zhang Q: Monotropein protects against
inflammatory bone loss and suppresses osteoclast formation and bone
resorption by inhibiting NFATc1 via NF-κB and Akt/GSK-3β pathway.
Nutrients. 14:39782022. View Article : Google Scholar
|
|
47
|
Fan X, Xiong H, Wei J, Gao X, Feng Y, Liu
X, Zhang G, He QY, Xu J and Liu L: Cytoplasmic hnRNPK interacts
with GSK3β and is essential for the osteoclast differentiation. Sci
Rep. 5:177322015. View Article : Google Scholar
|
|
48
|
Yang S, Song D, Wang Z, Su Y, Chen J, Xian
Y, Huang J, Li J, Xu J, Zhao J and Liu Q: AKT/GSK3β/NFATc1 and ROS
signal axes are involved in AZD1390-mediated inhibitory effects on
osteoclast and OVX-induced osteoporosis. Int Immunopharmacol.
113:1093702022. View Article : Google Scholar
|
|
49
|
Song I, Kim JH, Kim K, Jin HM, Youn BU and
Kim N: Regulatory mechanism of NFATc1 in RANKL-induced osteoclast
activation. FEBS Lett. 583:2435–2440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Meng B, Wu D, Cheng Y, Huang P, Liu Y, Gan
L, Liu C and Cao Y: Interleukin-20 differentially regulates bone
mesenchymal stem cell activities in RANKL-induced
osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB,
MAPK and AKT signalling pathways. Scand J Immunol. 91:e128742020.
View Article : Google Scholar
|
|
51
|
Jiang T, Gong Y, Zhang W, Qiu J, Zheng X,
Li Z, Yang G and Hong Z: PD0325901, an ERK inhibitor, attenuates
RANKL-induced osteoclast formation and mitigates cartilage
inflammation by inhibiting the NF-κB and MAPK pathways. Bioorg
Chem. 132:1063212023. View Article : Google Scholar
|
|
52
|
Lee ZH, Lee SE, Kim CW, Lee SH, Kim SW,
Kwack K, Walsh K and Kim HH: IL-1alpha stimulation of osteoclast
survival through the PI 3-kinase/Akt and ERK pathways. J Biochem.
131:161–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chaisson ML, Branstetter DG, Derry JM,
Armstrong AP, Tometsko ME, Takeda K, Akira S and Dougall WC:
Osteoclast differentiation is impaired in the absence of inhibitor
of kappa B kinase alpha. J Biol Chem. 279:54841–54848. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chu J, Yan B, Zhang J, Peng L, Ao X, Zheng
Z, Jiang T and Zhang Z: Casticin attenuates osteoarthritis-related
cartilage degeneration by inhibiting the ROS-Mediated NF-κB
signaling pathway in vitro and in vivo. Inflammation. 43:810–820.
2020. View Article : Google Scholar : PubMed/NCBI
|
